■随着癌症诊断工具和治疗方式的重大进展,在过去的几十年中,多原发恶性肿瘤(MPM)的发病率有所增加。治疗选择随着免疫检查点抑制剂(ICIs)的出现而改变,提高了广谱肿瘤的存活率。然而,关于疗效的信息很少,阻力,以及ICI的潜在机制。
■一名67岁女性被诊断为肺肉瘤样癌(PSC),有肝细胞癌(HCC)和病毒性乙型肝炎病史。她接受了Camrelizumab的治疗,抗程序性细胞死亡蛋白1单克隆抗体,结合化疗,PSC和HCC均获得部分缓解。经过9个月的疗程,PSC病变仍然缩小,虽然HCC被评估为一种进行性疾病,肝脏肿瘤的直径增加,甲胎蛋白升高,和腹部淋巴结肿大。然后,加上腹部转移的放射治疗,肺部病变持续缩小。同时,肝肿瘤和腹部淋巴结未见明显肿大。
■Camrelizumab联合治疗可持续受益于PSC和HCC的MPM患者,对于MPM患者来说,这可能是一个有希望的选择。
UNASSIGNED: With significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the survival of a broad spectrum of tumors. However, little information is available when it comes to the efficacy, resistance, and underlying mechanisms of ICIs.
UNASSIGNED: A 67-year-old woman was diagnosed with pulmonary sarcomatoid carcinoma (PSC) with a history of hepatocellular carcinoma (HCC) and viral hepatitis B. Following the lack of response to systemic chemotherapy, she was treated with camrelizumab, an anti-programmed cell death protein 1 monoclonal antibody, in combination with chemotherapy, and a partial response was obtained both in PSC and HCC. After a course of 9-month treatment, the PSC lesion shrank still, while HCC was evaluated as a progressive disease with an increase in the diameter of liver neoplasm, elevated alpha-fetoprotein, and enlarged abdominal lymph nodes. Then, with the addition of radiotherapy for abdominal metastasis, the lung lesion was continuously shrinking. In the meantime, the liver neoplasm and abdominal lymph nodes showed no significant enlargement.
UNASSIGNED: Camrelizumab combination therapy could consistently benefit the MPM patients with PSC and HCC, which may be a promising option for patients with MPMs.